-
Innovation Ranking
NewInnovation Ranking – Ipsen SA
Ipsen SA (Ipsen) is a global specialty biopharmaceutical company engaged in the manufacturing and distribution of drugs for the treatment of cancer, rare diseases, and neurological diseases, including specialty pharmaceutical products. The company develops and commercializes novel medicines for cancer, neuroscience and rare diseases and offers products to treat gastrointestinal disorders, and neurodegenerative pathologies. Ipsen sells its drugs through a network of distributors and directly to hospitals in a few countries. The company operates its research and development facilities in...
-
Product Insights
NewNet Present Value Model: Ipsen SA’s Elafibranor
Empower your strategies with our Net Present Value Model: Ipsen SA's Elafibranor report and make more profitable business decisions.Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Company Insights
Innovation and Patenting activity of Ipsen SA Q4 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of Ipsen SA Q4 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will be delivered...
-
Product Insights
NewNet Present Value Model: Eli Lilly and Co’s Imlunestrant Tosylate
Empower your strategies with our Net Present Value Model: Eli Lilly and Co's Imlunestrant Tosylate report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewPolycystic Kidney Disease Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2024 Update
Polycystic Kidney Disease Clinical Trial Report Overview A total of 238 polycystic kidney disease clinical trials were conducted as of March 2024. The polycystic kidney disease clinical trial report provides a comprehensive understanding of the polycystic kidney disease clinical trial scenario across regions, and countries (G7 & E7), along with insights into the various phases, trial status, and end points status. The report also includes information about the sponsor types and the prominent sponsors associated with the trials. Key Regions...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – TIN-816 in Sepsis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - TIN-816 in Sepsis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. TIN-816 in Sepsis Drug Details: TIN-816 is under development for the treatment of...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – INV-1120 in Liver Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - INV-1120 in Liver Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. INV-1120 in Liver Cancer Drug Details: INV-1120 is under development for the...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Pinometostat in Refractory Acute Myeloid Leukemia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Pinometostat in Refractory Acute Myeloid Leukemia report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Pinometostat in Refractory Acute Myeloid Leukemia Drug Details: Pinometostat (EPZ-5676)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – STAR-0602 in Merkel Cell Carcinoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - STAR-0602 in Merkel Cell Carcinoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. STAR-0602 in Merkel Cell Carcinoma Drug Details: STAR-0602 is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Elafibranor in Primary Biliary Cholangitis (Primary Biliary Cirrhosis)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Elafibranor in Primary Biliary Cholangitis (Primary Biliary Cirrhosis) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Elafibranor in Primary Biliary Cholangitis (Primary Biliary Cirrhosis)...